Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Spyre touts ph. 2 UC win as proof it could surpass Entyvio
Spyre’s monoclonal antibody hit the key goal in a phase 2 study for ulcerative colitis, which the company touted as proof it can best Takeda’s Entyvio.
James Waldron
Apr 13, 2026 9:55am
Merck hands over $20M in IBD target deal with Quotient
Mar 24, 2026 6:00am
Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug
Mar 4, 2026 3:07am
Rasayana Tx ingests GI candidate in $36M deal
Feb 18, 2026 10:40am
Sanofi points to long-term efficacy of Teva-partnered IBD drug
Feb 17, 2026 8:05am
Boehringer pens €1.05B deal for Simcere's IBD bispecific
Jan 27, 2026 7:30am
